Viewing Study NCT06816992

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:15 PM
Ignite Modification Date: 2026-01-07 @ 7:19 AM
Study NCT ID: NCT06816992
Status: RECRUITING
Last Update Posted: 2025-03-20
First Post: 2025-02-03
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
Sponsor: ORIC Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Tumors View
None EGFR Exon 20 Insertion Mutations View
None NSCLC View
None EGFR-mutated NSCLC View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NSCLC View
None EGFR mutations View
None EGFR exon20 View
None EGFR exon 20 insertion mutations View
None ORIC-114 View
None Amivantamab View